Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study) - Sorbonne Université
Article Dans Une Revue BMJ Open Année : 2023

Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study)

Aurore Dougé
  • Fonction : Auteur
Aurélie Ravinet
  • Fonction : Auteur
  • PersonId : 1297364
Alexandrine Corriger
Aurélie Cabrespine
  • Fonction : Auteur
Mathieu Wasiak
  • Fonction : Auteur
Bruno Pereira
  • Fonction : Auteur
Harry Sokol
  • Fonction : Auteur

Résumé

Allogeneic haematopoietic stem-cell transplantation (allo-HSCT) is a major treatment for many haematological malignancies. The procedure has a good success rate but high transplant-related toxicity (TRM). TRM is mostly related to graft-versus- host disease (GvHD) and infectious complications. Alterations of the intestinal microbiota plays a major role in the development of allo- HSCT complications. The gut microbiota could be restored by faecal microbiota transplantation (FMT). However, there are no published randomised studies assessing the efficacy of FMT for GvHD prophylaxis.
Fichier principal
Vignette du fichier
e068480.full.pdf (457.88 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-04251279 , version 1 (20-10-2023)

Identifiants

Citer

Aurore Dougé, Aurélie Ravinet, Alexandrine Corriger, Aurélie Cabrespine, Mathieu Wasiak, et al.. Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study). BMJ Open, 2023, 13 (5), pp.1-10. ⟨10.1136/bmjopen-2022-068480⟩. ⟨hal-04251279⟩
30 Consultations
13 Téléchargements

Altmetric

Partager

More